No Data
Alphamab Oncology Gets Breakthrough Designation for Anti-Cancer Drug; Shares Surge 24%
ALPHAMAB-B (09966.HK): JSKN003 has received breakthrough therapy designation from the National Medical Products Administration.
On March 18, Gelonghui announced that ALPHAMAB-B (09966.HK) released an announcement stating that JSKN003 has received breakthrough therapy designation from the National Medical Products Administration ("National Medical Products Administration") for the treatment of platinum-resistant recurrent epithelial ovarian cancer ("PROC"), primary peritoneal cancer, or fallopian tube cancer, regardless of human epidermal growth factor receptor 2 ("HER2") expression levels. This breakthrough therapy designation is based on the summarized analysis results of two clinical studies, JSKN003-101 and JSKN003-102. JSKN003-101 is a
Express News | Alphamab Oncology - Jskn003 Was Granted Breakthrough Therapy Designation by Nmpa
Alphamab Oncology (HKG:9966 Shareholders Incur Further Losses as Stock Declines 8.7% This Week, Taking Five-year Losses to 60%
Hong Kong stock movement | ALPHAMAB-B (09966) fell over 14% in the morning session as the company was removed from the Hong Kong Stock Connect list, previously expected to achieve annual profitability for the first time.
ALPHAMAB-B (09966) fell over 14% in early trading, as of the time of writing, it has dropped 12.85%, priced at 5.29 HKD, with a transaction value of 17.1259 million HKD.
ALPHAMAB-B (09966.HK) plans to hold a Board of Directors meeting on March 25 to approve the annual performance.
Gelonghui reported on March 6 that ALPHAMAB-B (09966.HK) announced that the Board of Directors will hold a meeting on Tuesday, March 25, 2025, to consider and approve the annual performance and its announcement of the company and its subsidiaries for the year ended December 31, 2024, as well as address Other matters.
Alphamab Oncology's (HKG:9966) 31% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
